Literature DB >> 33138752

Current Studies of Aspirin as an Anticancer Agent and Strategies to Strengthen its Therapeutic Application in Cancer.

Phuong H L Tran1, Beom-Jin Lee2, Thao T D Tran3.   

Abstract

Aspirin has emerged as a promising intervention in cancer in the past decade. However, there are existing controversies regarding the anticancer properties of aspirin as its mechanism of action has not been clearly defined. In addition, the risk of bleeding in the gastrointestinal tract from aspirin is another consideration that requires medical and pharmaceutical scientists to work together to develop more potent and safe aspirin therapy in cancer. This review presents the most recent studies of aspirin with regard to its role in cancer prevention and treatment demonstrated by highlighted clinical trials, mechanisms of action as well as approaches to develop aspirin therapy best beneficial to cancer patients. Hence, this review provides readers with an overview of aspirin research in cancer that covers not only the unique features of aspirin, which differentiate aspirin from other non-steroidal anti-inflammatory drugs (NSAIDs), but also strategies that can be used in the development of drug delivery systems carrying aspirin for cancer management. These studies convey optimistic messages on the continuing efforts of the scientist on the way of developing an effective therapy for patients with a low response to current cancer treatments. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Aspirin; cancer; drug delivery systems.; mechanism of action; prevention; treatment

Year:  2021        PMID: 33138752     DOI: 10.2174/1381612826666201102101758

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

1.  Innovative targets of the lncRNA-miR-mRNA network in response to low-dose aspirin in breast cancer patients.

Authors:  Sadaf Alipour; Solmaz Khalighfard; Vahid Khori; Taghi Amiriani; Mahboubeh Tajaldini; Mohammad Dehghan; Somayeh Sadani; Ramesh Omranipour; Gelareh Vahabzadeh; Bita Eslami; Ali Mohammad Alizadeh
Journal:  Sci Rep       Date:  2022-07-14       Impact factor: 4.996

2.  Pathological Significance and Prognostic Roles of Thrombospondin-3, 4 and 5 in Bladder Cancer.

Authors:  Junki Harada; Yasuyoshi Miyata; Kyohei Araki; Tsuyoshi Matsuda; Yoshiaki Nagashima; Yuta Mukae; Kensuke Mistunari; Tomohiro Matsuo; Kojiro Ohba; Yasushi Mochizuki; Hideki Sakai
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.